Physician profile
Thomas Michael Meirick
NPI 1417448408
$9,149.34
in general payments reported to CMS, 2019-2025
8 companies · $6,756 in 2025
The $6,756 reported for 2025 was more than what 92% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $304 · 2024: $2,090 · 2025: $6,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,834 · Consulting Fee: $4,288 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,834.06 |
| Consulting Fee | $4,287.50 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $4,556.62 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Alcon Vision LLC | $2,368.34 | 2023-2025 | Clareon, Centurion, Acrysof Iq Panoptix Uv Iol |
| Glaukos Corporation | $1,043.46 | 2023-2025 | Kxl System, Idose, Kxl System (Not Refurbished) |
| Dompe US, INC. | $564.53 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $331.62 | 2024-2025 | Stellaris, Xiidra, Miebo |
| Sight Sciences, INC. | $133.18 | 2023-2024 | Omni Surgical System |
| Amgen INC. | $121.73 | 2024 | Tepezza |
| Neurotech Pharmaceuticals, INC. | $29.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Meirick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.